| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | 5194-IL-025/CF | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier-Free | NBP2-35040-1mg | |||
| Carrier-Free | NBP2-35040-100ug | |||
| Carrier-Free | NBP2-35040-500ug | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | 5390-IL-025/CF | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-24765SS | |||
| Azide and BSA Free | NBP2-46611 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | IC7211G-100UG | |||
| Carrier Free | IC7211R-100UG | |||
| Carrier Free | MAB7211-SP | |||
| Carrier Free | IC7211P-100UG | |||
| Carrier Free | IC7211V-100UG | |||
| Carrier Free | IC7211U-100UG | |||
| Carrier Free | IC7211T-100UG | |||
| Carrier Free | IC7211S-100UG | |||
| Carrier Free | IC7211N-100UG | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | 8410-IL-025/CF | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | 9340-IL-025/CF | |||
![Immunohistochemistry-Paraffin: IL-17/IL-17A Antibody (TC11-18H10) - Azide and BSA Free [NBP1-72027] - IL-17/IL-17A Antibody (TC11-18H10) [NBP1-72027] - Treatment with HBOT or PFD decreased IL-17A expression in the AD lesions. IHC for IL-17A on mouse skin. Scale bar is 100 um. The number of IL-17A-expressing cells was counted in five high-power fields (HPF) chosen at random in each slide by three different pathologists. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0109297) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/IL-17-IL-17A-Antibody-TC11-18H10-Immunohistochemistry-Paraffin-NBP1-72027-img0003.jpg "Immunohistochemistry-Paraffin: IL-17/IL-17A Antibody (TC11-18H10) - Azide and BSA Free [NBP1-72027] - IL-17/IL-17A Antibody (TC11-18H10) [NBP1-72027] - Treatment with HBOT or PFD decreased IL-17A expression in the AD lesions. IHC for IL-17A on mouse skin. Scale bar is 100 um. The number of IL-17A-expressing cells was counted in five high-power fields (HPF) chosen at random in each slide by three different pathologists. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0109297) licensed under a CC-BY license.")
![Immunohistochemistry-Paraffin: IL-17/IL-17A Antibody (TC11-18H10) [NBP1-72027] - Analysis of anti-IL-17 antibody of mouse spleen at concentration 10 ug/ml.](http://images.novusbio.com/fullsize/IL-17-IL-17A-Antibody-TC11-18H10-Immunohistochemistry-Paraffin-NBP1-72027-img0002.jpg)
![Immunocytochemistry/ Immunofluorescence: IL-17/IL-17A Antibody (TC11-18H10) - Azide and BSA Free [NBP1-72027] - TG2-dependent chemokine production in keratinocytes is critical for IL-17-producing CCR6+ gamma δT-cell & neutrophil dermal infiltration.a, b Effect of DMSO- or IMQ-treated WT- or TG2−/−-CM on CCR6+ gamma δT-cell (a) & CD11b+ Ly-6G+ cell (b) migration according to Transwell migration assays. Flow cytometric analysis of the percentage of cells migrating toward the CM in the presence or absence of anti-CXCL1 (a) & anti-CCL20 (b) antibodies (n = 3/group). c, d WT & TG2−/− mouse-derived CCR6+ gamma δT-cell (c) & CD11b+ Ly-6G+ cell (d) migration in response to recombinant mouse CCL20 & CXCL1, respectively. Data represent the mean ± SEM (n = 3/group). *p < 0.05; **p < 0.01. e, f Cells were isolated from the back skin of WT & TG2−/− mice treated with IMQ for four consecutive days & analyzed by flow cytometry. Representative flow cytometric profiles of CCR6+ gamma δTCRlow cells (e) & CD11bhigh Ly-6G+ cells (f). The percentage of cells is shown. Data represent the mean ± SEM (n = 9/group). g Skin sections were immunostained with CCR6 (green)- & IL-17 (red)-specific antibodies. Nuclei were stained with DAPI (blue). Scale bar, 100 μm. h–j Back skin was separated into epidermis & dermis & analyzed by RT-PCR for IL-17-producing gamma δT-cell markers (h) (Ccr6 & Il23r), IL17 & related cytokines (i) (Il17a, Il17f, & Il22), & myeloid cell-derived cytokines (j) (Il12a & Il23a). Data represent the mean ± SEM (n = 11/group). *p < 0.05; **p < 0.01 vs. WT mice. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32355189), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-72027_rat-il-17-il-17a-mab-tc11-18h10-azide-and-bsa-free-310202416171471.jpg)
![SDS-Page: Human IL-17/IL-17A Protein [NBP2-35040]](http://images.novusbio.com/fullsize/Human-IL-17-IL-17A-Protein-SDS-Page-NBP2-35040-img0001.jpg "SDS-Page: Human IL-17/IL-17A Protein [NBP2-35040]")
![Western Blot: IL-17/IL-17A Antibody [NBP3-13294] - Mouse tissue extract (50 ug) was separated by 15% SDS-PAGE, and the membranes were blotted with IL-17/IL-17A antibody (NBP3-13294) diluted at 1:1000 and competitor's antibody diluted at 1:100. The HRP-conjugated anti-rabbit IgG antibody (NBP2-19301) was used to detect the primary antibody.](http://images.novusbio.com/fullsize/IL-17-IL-17A-Antibody-Western-Blot-NBP3-13294-img0005.jpg "<b>Independent Antibodies Validation. </b>Western Blot: IL-17/IL-17A Antibody [NBP3-13294] - Mouse tissue extract (50 ug) was separated by 15% SDS-PAGE, and the membranes were blotted with IL-17/IL-17A antibody (NBP3-13294) diluted at 1:1000 and competitor's antibody diluted at 1:100. The HRP-conjugated anti-rabbit IgG antibody (NBP2-19301) was used to detect the primary antibody.")
![<b>Independent Antibodies Validation. </b>Immunohistochemistry-Paraffin: IL-17/IL-17A Antibody [NBP3-13294] - Human colon. IL-17/IL-17A stained by IL-17/IL-17A antibody (NBP3-13294) diluted at 1:2000. Antigen Retrieval: Citrate buffer, pH 6.0, 15 min.](http://images.novusbio.com/fullsize/IL-17-IL-17A-Antibody-Immunohistochemistry-Paraffin-NBP3-13294-img0003.jpg)
![Western Blot: IL-17/IL-17A Antibody [NBP3-13294] - Non-transfected (-) and transfected (+) 293T whole cell extracts (30 ug) were separated by 15% SDS-PAGE, and the membrane was blotted with IL-17/IL-17A antibody (NBP3-13294) diluted at 1:5000. The HRP-conjugated anti-rabbit IgG antibody (NBP2-19301) was used to detect the primary antibody.](http://images.novusbio.com/fullsize/IL-17-IL-17A-Antibody-Western-Blot-NBP3-13294-img0001.jpg)
![Western Blot: IL-17/IL-17A Antibody [NBP3-13294] - Rat tissue extract (50 ug) was separated by 15% SDS-PAGE, and the membrane was blotted with IL-17/IL-17A antibody (NBP3-13294) diluted at 1:1000. The HRP-conjugated anti-rabbit IgG antibody (NBP2-19301) was used to detect the primary antibody, and the signal was developed with Trident ECL plus-Enhanced.](http://images.novusbio.com/fullsize/IL-17-IL-17A-Antibody-Western-Blot-NBP3-13294-img0004.jpg)
![Immunohistochemistry-Paraffin: IL-17/IL-17A Antibody [NBP3-13294] - Human colon cancer. IL-17/IL-17A stained by IL-17/IL-17A antibody (NBP3-13294) diluted at 1:2000. Antigen Retrieval: Citrate buffer, pH 6.0, 15 min.](http://images.novusbio.com/fullsize/IL-17-IL-17A-Antibody-Immunohistochemistry-Paraffin-NBP3-13294-img0002.jpg)
![Western Blot: IL-17/IL-17A Antibody (4k5F6) [NBP2-24765] - Analysis of human serum (albumin-depleted) (1), human plasma (albumin-depleted) (2), and human lymph node tissue (3) using IL17 antibody at a concentration of 2 ug/mL.](http://images.novusbio.com/fullsize/IL-17-IL-17A-Antibody-4k5F6-Western-Blot-NBP2-24765-img0004.jpg "Western Blot: IL-17/IL-17A Antibody (4k5F6) [NBP2-24765] - Analysis of human serum (albumin-depleted) (1), human plasma (albumin-depleted) (2), and human lymph node tissue (3) using IL17 antibody at a concentration of 2 ug/mL.")
![Western Blot: IL-17/IL-17A Antibody (4k5F6) [NBP2-24765] - Analysis of 1) human, 2) mouse and 3) rat full-length recombinant IL-17A protein using IL-17A antibody at 0.2 ug/mL.](http://images.novusbio.com/fullsize/IL-17-IL-17A-Antibody-4k5F6-Western-Blot-NBP2-24765-img0003.jpg)
